CoChat
Sign Up
Cited by 292Acute Myeloid Leukemia ResearchErythropoietin and Anemia TreatmentHematopoietic Stem Cell Transplantation

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

Platzbecker, Uwe, Germing, Ulrich, Götze, Katharina S, Kiewe, Philipp, Mayer, Karin, Chromik, Jörg, Radsak, Markus, Wolff, Thomas, Zhang, Xiaosha, Laadem, Abderrahmane, Sherman, Matthew L, Attie, Kenneth M, Giagounidis, Aristoteles·2017·The Lancet Oncology
DOI 10.1016/s1470-2045(17)30615-0
Open this paper in CoChat — free account

Abstract

Background Myelodysplastic syndromes are characterised by ineffective erythropoiesis. Luspatercept (ACE-536) is a novel fusion protein that blocks transforming growth factor beta (TGF β) superfamily inhibitors of erythropoiesis, giving rise to a promising new investigative therapy. We aimed to assess the safety and efficacy of luspatercept in patients with anaemia due to lower-risk myelodysplastic syndromes. Methods In this phase 2, multicentre, open-label, dose-finding study (PACE-MDS), with long-term extension, eligible patients were aged 18 years or older, had International Prognostic Scoring System-defined low or intermediate 1 risk myelodysplastic syndromes or non-proliferative chronic myelomonocytic leukaemia (white blood cell count <13 000/μL), and had anaemia with or without red blood cell transfusion support. Enrolled patients were classified as having low transfusion burden, defined as requiring less than 4 red blood cell units in the 8 weeks before treatment (and baseline haemoglobin <10 g/dL), or high transfusion burden, defined as requiring 4 or more red blood cell units in the 8 weeks before treatment. Patients received luspatercept subcutaneously once every 21 days at dose concentrations ranging from 0·125 mg/kg to 1·75 mg/kg bodyweight for five doses (over a maximum of 12 weeks). Patients in the expansion cohort were treated with 1·0 mg/kg luspatercept; dose titration up to 1·75 mg/kg was allowed, and patients could be treated with luspatercept for a maximum of 5 years. Patients in the base study were assessed for response and safety after 12 weeks in order to be considered for enrolment into the extension study. The primary endpoint was the proportion of patients achieving modified International Working Group-defined haematological improvement-erythroid (HI-E), defined as a haemoglobin concentration increase of 1·5 g/dL or higher from baseline for 14 days or longer in low transfusion burden patients, and a reduction in red blood cell transfusion of 4 or more red blood cell units or a 50% or higher reduction in red blood cell units over 8 weeks versus pre-treatment transfusion burden in high transfusion burden patients. Patient data were subcategorised by: luspatercept dose concentrations (0·125-0·5 mg/kg vs 0·75-1·75 mg/kg); pre-study transfusion burden (high transfusion burden vs low transfusion burden, defined as ≥4 vs <4 red blood cell units per 8 weeks); pre-study serum erythropoietin concentration (<200 IU/L, 200-500 IU/L, and >500 IU/L); presence of 15% or more ring sideroblasts; and presence of SF3B1 mutations. Efficacy analyses were carried out on the efficacy evaluable and intention-to-treat populations. This trial is currently ongoing. This study is registered with ClinicalTrials.gov, numbers NCT01749514 and NCT02268383. Findings Between Jan 21, 2013, and Feb 12, 2015, 58 patients with myelodysplastic syndromes were enrolled in the 12 week base study at nine treatment centres in Germany; 27 patients were enrolled in the dose-escalation cohorts (0·125-1·75 mg/kg) and 31 patients in the expansion cohort (1·0-1·75 mg/kg). 32 (63% [95% CI 48-76]) of 51 patients receiving higher dose luspatercept concentrations (0·75-1·75 mg/kg) achieved HI-E versus two (22% [95% CI 3-60]) of nine receiving lower dose concentrations (0·125-0·5 mg/kg). Three treatment-related grade 3 adverse events occurred in one patient each: myalgia (one [2%]), increased blast cell count (one [2%]), and general physical health deterioration (one [2%]). Two of these treatment-related grade 3 adverse events were reversible serious grade 3 adverse events: one patient (2%) had myalgia and one patient (2%) had general physical health deterioration. Interpretation Luspatercept was well tolerated and effective for the treatment of anaemia in lower-risk myelodysplastic syndromes and so could therefore provide a novel therapeutic approach for the treatment of anaemia associated with lower-risk myelodysplastic syndromes; further studies are ongoing. Funding Acceleron Pharma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(17)30615-0

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

Sorted by citations

Items 201–290 of 290

Related

See all

Metadata

Authors
Platzbecker, U., Germing, U., Götze, K. S., Kiewe, P., Mayer, K., Chromik, J., Radsak, M., Wolff, T., Zhang, X., Laadem, A., Sherman, M. L., Attie, K. M., & Giagounidis, A.
Affiliations
  • University Hospital Carl Gustav Carus (DE)
  • Düsseldorf University Hospital (DE)
  • Technical University of Munich (DE)
  • Stiftung Oskar Helene Heim (DE)
  • University Hospital Bonn (DE)
  • Goethe University Frankfurt (DE)
  • Johannes Gutenberg University Mainz (DE)
  • Acceleron Pharma (United States) (US)
  • Celgene (United States) (US)
  • Marien Hospital Düsseldorf (DE)
Corresponding author
Platzbecker, Uwe
ORCID
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2017-10
Volume
18
Issue
10
Pages
1338-1347
ISSN
1470-2045 (ISSN-L)
DOI
10.1016/s1470-2045(17)30615-0
OpenAlex
W2752628798
Cited by
292
References
24
Citations by year
2026: 9 · 2025: 19 · 2024: 22 · 2023: 25 · 2022: 26 · 2021: 45 · 2020: 46 · 2019: 54 · 2018: 43 · 2017: 3
FWCI
29.88
Type
journal article
Language
en
Update notices
erratum (2017-10-01)
Open access
closed
Licence
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion)
Funders
Acceleron
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords
luspatercept, myelodysplastic syndrome, anemia, erythropoiesis, TGF-beta inhibition, dose-finding, hemoglobin response, red blood cell transfusion, chronic myelomonocytic leukemia, transfusion burden, long-term extension study, safety, efficacy, low-risk MDS
MeSH terms
Adult, Aged, Anemia, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Germany, Humans, Immunoglobulin Fc Fragments, Male, Middle Aged, Myelodysplastic Syndromes, Prognosis, Prospective Studies, Recombinant Fusion Proteins, Severity of Illness Index, Time Factors, Proportional Hazards Models, Survival Analysis, Treatment Outcome, Risk Assessment, Disease-Free Survival, Maximum Tolerated Dose, Activins, Activin Receptors, Type II, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review